SCHEMBL13680718

SCHEMBL13680718

Cc1ccc(-c2cnc(N)nc2)o1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.39
HPGD P15428 4/20 0.39
TDP1 Q9NUW8 3/20 0.39
HSD17B10 Q99714 3/20 0.39
KDM4E B2RXH2 3/20 0.39
GAA P10253 3/20 0.39
LMNA P02545 2/20 0.39
NPC1 O15118 1/20 0.39
TSHR P16473 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPT P10636 4/20 0.38
HTT P42858 3/20 0.38
POLB P06746 1/20 0.38
THRB P10828 1/20 0.38
RECQL P46063 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ALOX5AP P20292 1/20 0.38
FEN1 P39748 1/20 0.38
ADORA2A P29274 4/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13680715 0.83 TDP1 (0.42) ALDH1A1HPGDTDP1HSD17B10KDM4E
SCHEMBL13680711 0.80 ALDH1A1 (0.39) ALDH1A1HPGDTDP1HSD17B10KDM4E
SCHEMBL13680518 0.77 MAPT (0.41) ALDH1A1HPGDTDP1HSD17B10KDM4E
SCHEMBL13680700 0.77 MAP4K4 (0.41) ALDH1A1HPGDTDP1HSD17B10KDM4E
SCHEMBL13680709 0.77 GRM5 (0.37) ALDH1A1HPGDTDP1HSD17B10KDM4E
SCHEMBL13680720 0.77 GSK3B (0.38) ALDH1A1HPGDTDP1HSD17B10KDM4E
SCHEMBL13680469 0.76 NPC1 (0.42) ALDH1A1HPGDTDP1HSD17B10KDM4E
SCHEMBL13680704 0.76 SMN1; SMN2 (0.53) ALDH1A1HPGDHSD17B10KDM4EGAA
SCHEMBL13681360 0.76 ALDH1A1 (0.40) ALDH1A1HPGDTDP1HSD17B10KDM4E
SCHEMBL13681358 0.76 ALDH1A1 (0.36) ALDH1A1HPGDTDP1HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230080054-A1 INHIBITORS OF ANOCTAMIN 6 PROTEIN AND USES THEREOF ILDONG PHARMACEUTICAL CO., LTD. (KR) 2023-03-16 US disclosed
WO-2022195522-A1 INHIBITORS OF ANO6 AND THEIR USES THEREOF ILDONG PHARMACEUTICAL CO., LTD. (KR) 2022-09-22 WO disclosed
WO-2022157686-A1 INHIBITORS OF ANOCTAMIN 6 PROTEIN AND USES THEREOF ILDONG PHARMACEUTICAL CO., LTD. (KR) 2022-07-28 WO disclosed
US-7582658-B2 Bicyclic compound ASAHI KASEI PHARMA CORPORATION (JP) 2009-09-01 US disclosed
US-7582658-B2 Bicyclic compound ASAHI KASEI PHARMA CORPORATION (JP) 2009-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230080054-A1 INHIBITORS OF ANOCTAMIN 6 PROTEIN AND USES THEREOF ANO1, ANO2, CACYBP ALDH1A1 2515/4885HPGD 4011/4885TDP1 3858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.